229 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
14
Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Xinxiang Medical University
9
Discovery of [1,2,3]Triazolo[4,5-
Key Laboratory of Technology of Drug Preparation (Zhengzhou University)
4
Activation of lysine-specific demethylase 1 inhibitor peptide by redox-controlled cleavage of a traceless linker.
Nagoya City University
10
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
Tu Dortmund University
1
Efficient synthesis of new antiproliferative steroidal hybrids using the molecular hybridization approach.
Zhengzhou University
10
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Kyoto Prefectural University of Medicine
6
Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide.
Waseda University
46
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
Baylor College of Medicine
11
Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.
Shandong University
5
Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies.
Sapienza University of Rome
11
Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.
Sapienza University of Rome
47
Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
Zhengzhou University
6
Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures.
John Hopkins University
19
Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
European Institute of Oncology
8
Synthesis and evaluation of novel cyclic Peptide inhibitors of lysine-specific demethylase 1.
Medical University of South Carolina
37
High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors.
University of Utah
85
Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.
Zhengzhou University
9
Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
University of Freiburg
2
Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1.
Wayne State University
2
(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators.
Wayne State University
16
Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
University of Southampton
3
Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.
Nagoya City University
32
Discovery of novel tranylcypromine-indazole-based derivatives as LSD1 inhibitors for acute myeloid leukemia treatment.
Zhengzhou University
38
Discovery of Novel 5-Cyano-3-phenylindole-Based LSD1/HDAC Dual Inhibitors for Colorectal Cancer Treatment.
Xinxiang Medical University
5
Benzothiazole a privileged scaffold for Cutting-Edges anticancer agents: Exploring drug design, structure-activity relationship, and docking studies.
Acharya & BM Reddy College of Pharmacy
13
Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids.
Taipei Medical University
13
Overview of the epigenetic/cytotoxic dual-target inhibitors for cancer therapy.
Gannan Medical University
8
Synthesis, optimization and antitumor activity evaluation of sulfonyl benzoyl hydrazide derivatives as novel human LSD1 inhibitors.
Sichuan University
6
Target Ligand Separation and Identification of Isoforsythiaside as a Histone Lysine-Specific Demethylase 1 Covalent Inhibitor Against Breast Cancer Metastasis.
China Pharmaceutical University
59
Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia.
Shenyang Pharmaceutical University
2
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Johns Hopkins University
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
37
Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer.
Zhenzhou University
21
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy.
Zhengzhou University
22
Discovery of new tetrahydroisoquinolines as potent and selective LSD1 inhibitors for the treatment of MLL-rearranged leukemia.
Zhejiang Ocean University
29
Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer.
Sun Yat-sen University Cancer Center
54
Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer.
Zhengzhou University
12
HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids.
Taipei Medical University
29
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
Sichuan University
38
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
Zhengzhou University
9
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment.
Guru Ghasidas University
50
Design, Synthesis, and Evaluation of the Selective and Orally Active LSD1 Inhibitor with the Potential of Treating Heart Failure.
Zhengzhou University
36
Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships.
Jiangxi Science & Technology Normal University
3
Design, synthesis, and biological evaluation of phenylcyclopropylamine-entinostat conjugates that selectively target cancer cells.
Kyoto Prefectural University of Medicine
16
Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment.
First Affiliated Hospital of Gannan Medical University
7
Covalent Peptide LSD1 Inhibitor Specifically Recognizes Cys360 in the Enzyme-Active Region.
Shenzhen University
3
Design, synthesis and biological evaluation of nitric oxide-releasing 5-cyano-6-phenyl-2, 4-disubstituted pyrimidine derivatives.
Zhengzhou University
13
Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors.
Henan University of Chinese Medicine
47
Identification of novel indole derivatives as highly potent and efficacious LSD1 inhibitors.
Shenyang Pharmaceutical University
3
Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers.
Zhengzhou University
29
Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer.
Zhengzhou University
26
Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
Zhengzhou University
14
Triazole-fused pyrimidines in target-based anticancer drug discovery.
Zhenzhou University
15
Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications.
Zhengzhou University
17
Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects.
Takeda Pharmaceutical
10
Research progress of LSD1-based dual-target agents for cancer therapy.
Xinxiang University
52
Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.
Xinxiang Medical University
26
Structural and Functional Landscape of FAD-Dependent Histone Lysine Demethylases for New Drug Discovery.
Zhengzhou University
48
Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells.
Zhengzhou University
8
Synthesis and evaluation of small molecule inhibitors of LSD1 for use against MYCN-expressing neuroblastoma.
Medical University of South Carolina
22
Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation.
Hunan University of Science and Technology
17
Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy.
Xinxiang Medical University
30
From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD).
University of S£O Paulo
32
Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Zhengzhou University
41
Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
Zhengzhou University
68
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Menoufia University
33
Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors.
Shanghai Institute of Materia Medica
9
-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment.
University of Southern California
15
Design and Synthesis of Tranylcypromine-Derived LSD1 Inhibitors with Improved hERG and Microsomal Stability Profiles.
Riken Center For Sustainable Resource Science
5
Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.
Kyoto Prefectural University of Medicine
47
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
Hangzhou Normal University
34
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
National Institute of Pharmaceutical Education and Research (NIPER)
10
A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.
Zhengzhou University
10
Combining monoamine oxidase B and semicarbazide-sensitive amine oxidase enzyme inhibition to address inflammatory disease.
Pharmaxis
13
Annual review of LSD1/KDM1A inhibitors in 2020.
Beijing University of Chinese Medicine
11
Structure-Based Identification of Potent Lysine-Specific Demethylase 1 Inhibitor Peptides and Temporary Cyclization to Enhance Proteolytic Stability and Cell Growth-Inhibitory Activity.
Nagoya City University
29
Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Xinxiang Medical University
16
Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
China Pharmaceutical University
40
Discovery of quinazoline derivatives as a novel class of potent and in vivo efficacious LSD1 inhibitors by drug repurposing.
Henan University of Chinese Medicine
42
Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Shenyang Pharmaceutical University
21
Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
Zhengzhou University
36
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Key Laboratory of Henan Provinc
26
Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
Wuhan University
27
Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
Jubilant Therapeutics India
5
[1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Henan University of Chinese Medicine
10
Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1).
Fount Therapeutics
59
Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Shenyang Pharmaceutical University
30
Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.
Constellation Pharmaceuticals
15
4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
Liaocheng University
33
Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models.
European Institute of Oncology Irccs
10
New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
Universidad San Pablo-Ceu
62
Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors.
Sichuan University
32
Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors.
Zhengzhou University
53
Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.
Zhengzhou University
32
Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors.
Zhengzhou University
17
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.
Liaoning Shihua University
11
Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
Taizhou People'S Hospital
9
Ligand-based design, synthesis and biological evaluation of xanthine derivatives as LSD1/KDM1A inhibitors.
Zhengzhou University
2
Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma.
West Virginia University
31
Design, synthesis and biological evaluation of curcumin analogues as novel LSD1 inhibitors.
Shenyang Pharmaceutical University
17
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.
China Pharmaceutical University
18
Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Xinxiang Medical University
25
Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Celgene
3
3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors.
Medical University of South Carolina
9
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Sapienza University of Rome
3
Recent advances in the development of polyamine analogues as antitumor agents.
Johns Hopkins University
60
Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
University of Freiburg
17
Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.
Fudan University
35
Structure-based design and discovery of potent and selective KDM5 inhibitors.
Celgene
1
New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
University of Nevada
3
Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Kyoto Prefectural University of Medicine
3
Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Waseda University
21
Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
Zhengzhou University
6
Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Potential Treatment for Different Types of Cancers.
Therachem Research Medilab (India)
22
Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
East China Normal University
10
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Xinxiang Medical University
19
Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1.
University of Manchester
36
Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
Zhengzhou University
27
Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
University of East Anglia
33
3D-QSAR (CoMFA, CoMSIA), molecular docking and molecular dynamics simulations study of 6-aryl-5-cyano-pyrimidine derivatives to explore the structure requirements of LSD1 inhibitors.
Zhengzhou University
39
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Genentech
32
Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1.
University of Manchester
35
Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1.
University of Manchester
14
Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
Nagoya City University
9
Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof
Scinnohub Pharmaceutical
45
SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
Mission Therapeutics
141
Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse
University Of Kentucky Research Foundation
39
MODIFIED BENZOFURAN-CARBOXAMIDES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
Merck Sharp & Dohme
10
Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
Janssen Pharmaceutica
314
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
Beijing Tide Pharmaceutical
93
Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors
Pfizer
71
3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
Board of Trustees of The Southern Illinois University
819
Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
Nimbus Saturn
27
Type of aryl benzofuran amidated derivative and medical use thereof
China Pharmaceutical University
80
Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
Legochem Biosciences
63
(S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor
AstraZeneca
90
Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
Boehringer Ingelheim International
150
5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis
Galapagos
179
Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
Allergan
11
Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
Forma Therapeutics
7
Compositions and methods for treating neoplasia, inflammatory disease and other disorders
Dana-Farber Cancer Institute
34
Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
Bristol Myers Squibb
31
Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
Bayer Intellectual Property
31
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
Euroscreen
10
Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof
Alla Chem
75
Heterocyclic amide derivatives as P2X7 receptor antagonists
Actelion Pharmaceuticals
13
Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): a focus on selectivity over arginase.
Christian-Albrechts-University
13
Synthesis of 5-amino-1,3,4-thiadiazole-2-sulphonamide derivatives and their inhibition effects on human carbonic anhydrase isozymes.
Dumlupinar University
7
Unusual activity pattern of leucine aminopeptidase inhibitors based on phosphorus containing derivatives of methionine and norleucine.
Academy of Sciences of The Czech Republic
23
Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.
Stony Brook University
39
Azetidine-substituted quinoxalines as opioid receptor like-1 modulators
Purdue Pharma
5
Reverse Biosynthesis: Generating Combinatorial Pools of Drug Leads from Enzyme-Mediated Fragmentation of Natural Products.
The University of Sydney
5
A L-lysine transporter of high stereoselectivity of the amino acid-polyamine-organocation (APC) superfamily: production, functional characterization, and structure modeling.
Max Planck Institute of Biophysics
4
Some Anticancer Agents Act on Human Serum Paraoxonase-1 to Reduce Its Activity.
Ahi Evran University
198
2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
Actelion Pharmaceuticals
16
Tri-aryl/heteroaromatic cannabinoids and use thereof
The University of Tennessee Research Foundation
17
Azetidine derivative and antidepressant composition including the same
Korea Institute of Science and Technology
30
Enzymatic Studies of Isoflavonoids as Selective and Potent Inhibitors of Human Leukocyte 5-Lipo-Oxygenase.
Universidad De Santiago
7
1,2-Diaryl-2-hydroxyiminoethanones as dual COX-1 and ß-amyloid aggregation inhibitors: biological evaluation and in silico study.
Mazandaran University of Medical Sciences
124
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
University of South Florida
5
Structure-based design of potent small-molecule binders to the S-component of the ECF transporter for thiamine.
University of Groningen
24
Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders
Vitae Pharmaceuticals
16
Dopamine D4 receptors bind inactive (+)-aporphines, suggesting neuroleptic role. Sulpiride not stereoselective.
University of Toronto
6
Structure-aided optimization of kinase inhibitors derived from alsterpaullone.
Technische UniversitÄT Braunschweig
448
ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES
Shanghai Yao Yuan Biotechnology Co.